| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 |
| filingDate |
2005-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3005c991db7f2f8252f5cc496e13813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd76644c106f615132696449299664e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d7c601ea26f2604e0d740bf4998048c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6dc91b9d3cae805086bfc4abf28233bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44d5fbed5d59bbd75d292098c9070428
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0aba3005bf0877abe003d21d5f7747f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc74fbad1004537e4f75e92b514a24de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21fd7fbb79f28d9512cc7fed659169f6 |
| publicationDate |
2007-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1773877-A1 |
| titleOfInvention |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
| abstract |
The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The peptides of this invention show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes. |
| priorityDate |
2004-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |